Surgical Treatment of Mitral Valve Regurgitation in Dilated Cardiomyopathy


  • Antonio M. Calafiore
  • Michele Di Mauro
  • Sabina Gallina
  • Ibrahim M. Yassin
  • Yousry A. Shaheen
  • Carlo Canosa
  • Angela L. Iacò
  • Valerio Mazzei



Background: Mitral valve (MV) surgery for dilated cardiomyopathy (DCM) was proposed at the beginning of the 1990s, and its effectiveness has been confirmed by many studies. The aim of this study is to evaluate long-term survival and the functional results of our experience with MV surgery for DCM.

Methods: From January 1990 to October 2002, MV surgery for DCM was performed in 91 patients (64 ischemic, 27 idiopathic). DCM was defined as in our previous reports. Patients with organic MV disease, severe right ventricle dilatation with impaired function, or severe renal or hepatic failure were excluded from the study. MV annuloplasty was performed in 64 patients, and 27 patients underwent a MV replacement.

Results: The 30-day mortality rate was 4.4% (4 patients). The probability of being alive at 5 years was 78.4% ± 4.3% and was higher in patients who underwent MV repair (81.4% ± 4.5%) than in patients who underwent replacement operation (66.7% ± 9.1%), even if the P value was not statistically significant. After a mean follow-up period of 27 ± 30 months, the New York Heart Association (NYHA) class decreased from 3.5 ± 0.7 to 2.1 ± 0.6 in the 69 survivors (P < .001). The probability of being alive 5 years after surgery with an improvement of least 1 NYHA class was 65.9% ± 5.0% and was higher in patients with MV repair (76.6% ± 6.0%) than in patients who underwent valve replacement (51.9% ± 9.6%), even if the P value was not statistically significant. Fifty patients were carefully followed with serial evaluations in our echocardiographic laboratory. Volumes did not change, nor did stroke volume or ejection fraction. Some degree of functional mitral regurgitation (FMR) was present in all but 8 of the patients who underwent repair. The analysis of these patients showed that all of the patients who had no residual MR had a mitral valve coaptation depth (MVCD) of 10 mm or less and had a better functional result. Conversely, the MVCD was shorter in patients who had no or mild (1/4) residual MR than in patients who had a residual MR >1/4. NYHA class was lower in patients with no or up to 1/4 residual MR, showing that the purpose of the procedure is the reduction or elimination of FMR, which is the determinant of the clinical result.

Conclusions: Long-term results in our patients are satisfying. FMR can be crucial for achieving a higher effectiveness of a combined strategy to improve the global outcome of these patients.


Radovanovic N, Mihajlovic B, Selestiansky J, et al. 2002. Reductive annuloplasty of double orifices in patients with primary dilated cardiomyopathy. Ann Thorac Surg 73:751-5.nRomeo F, Pelliccia F, Cianfrocca C, et al. 1989. Determinants of end-stage idiopathic dilated cardiomyopathy: a multivariate analysis of 104 patients. Clin Cardiol 12:387-92.nZile MR, Brutsaert DL. 2002. New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105:1387-93.nBadhwar V, Bolling SF. 2002. Mitral valve surgery: when is it appropriate? Congest Heart Fail 8:210-3.nBishay ES, McCarthy PM, Cosgrove PM, et al. 2000. Mitral valve surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg 17:213-21.nBlondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. 1991. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Heart J 122:763-71.nBolling SF, Deeb GM, Brunsting LA, Bach DS. 1995. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc Surg 109:676-83.nBolling SF, Pagani FD, Deeb GM, Bach DS. 1998. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 115:381-8.nBuffolo E, Paula IA, Palma H, Branco JN. 2000. A new surgical approach for treating dilated cardiomyopathy with mitral regurgitation [in English and Portuguese]. Arq Bras Cardiol 74:129-40.nCalafiore AM, Di Mauro M, Contini M, Vitolla G, Pelini P. 2003. Left ventricular volume reduction for dilated cardiomyopathy. In: Franco KL, Verrier ED, editors. Advanced therapy in cardiac surgery. 2nd ed. Hamilton, Ontario, Canada: BC Decker.nCalafiore AM, Di Mauro M, Gallina S, Canosa C, Iacò AL. 2003. Optimal length of pericardial strip for posterior mitral overreductive annuloplasty. Ann Thorac Surg 75:1982-4.nCalafiore AM, Gallina S, Contini M, et al. 1999. Surgical treatment of dilated cardiomyopathy with conventional technique. Eur J Cardiothorac Surg 16:S73-8.nCalafiore AM, Gallina S, Di Mauro M, et al. 2001. Mitral valve procedure in dilated cardiomyopathy: repair or replacement? Ann Thorac Surg 71:1146-53.nCalafiore AM, Teodori G, Mezzetti A, et al. 1995. Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg 59:398-402.nJunker A, Thayssen P, Nielsen B, Andersen PE. 1993. The hemodynamic and prognostic significance of echo-Doppler-proven mitral regurgitation in patients with dilated cardio-myopathy. Cardiology 83:14-20.nOtsuji Y, Handschumaker MD, Schwammenthal E, et al. 1997. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation 96:1999-2008.n



How to Cite

Calafiore, A. M., Mauro, M. D., Gallina, S., Yassin, I. M., Shaheen, Y. A., Canosa, C., Iacò, A. L., & Mazzei, V. (2005). Surgical Treatment of Mitral Valve Regurgitation in Dilated Cardiomyopathy. The Heart Surgery Forum, 7(1), E67-E71.




Most read articles by the same author(s)